Search results for "Pituitary ACTH hypersecretion"

showing 8 items of 8 documents

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

2017

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications

Pituitary glandmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpasireotide cushing diseaseSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDiabetes mellitusmedicineIn patientbusiness.industryPituitary ACTH hypersecretionRetrospective cohort studyCushing's diseasemedicine.diseasePasireotideSurgerymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisPituitary surgerybusinessEndocrine
researchProduct

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation

2022

Background: The primary objective of the study was to assess serum 25-hydroxyvitamin D [25(OH)D] values in patients with Cushing’s disease (CD), compared to controls. The secondary objective was to assess the response to a load of 150,000 U of cholecalciferol. Methods: In 50 patients with active CD and 48 controls, we evaluated the anthropometric and biochemical parameters, including insulin sensitivity estimation by the homeostatic model of insulin resistance, Matsuda Index and oral disposition index at baseline and in patients with CD also after 6 weeks of cholecalciferol supplementation. Results: At baseline, patients with CD showed a higher frequency of hypovitaminosis deficiency (p = 0…

cholecalciferolhypercortisolism.Nutrition and DieteticsDietary SupplementsHumansPituitary ACTH HypersecretionVitamin D Deficiencyglucocorticoid; hypercortisolism; 25-hydroxyvitamin D; cholecalciferol25-hydroxyvitamin DFood ScienceRicketsNutrients; Volume 14; Issue 5; Pages: 973
researchProduct

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

2018

Purpose: To evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing’s disease (CD). Methods: Clinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes mellituInjections SubcutaneousEndocrinology Diabetes and MetabolismAdipose tissueAdipokine030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAdipokinesInternal medicineDiabetes mellitusAdipokinemedicineHumansInsulinPituitary ACTH HypersecretionLeptin receptorAdiponectinbusiness.industryLeptinBody WeightMiddle AgedCushing’s diseasemedicine.diseaseInsulin sensitivityHormonesPasireotidePasireotideTreatment OutcomeEndocrinologychemistryFemaleResistinInsulin ResistanceSomatostatinbusiness
researchProduct

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

2019

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence. Thirty-two CD patients started pasireotide at the dose of 600 µg twice a day (bid) and with the chance of up-titration to 900 µg bid, or down-titration to 450 or 300 µg bid, on the basis of urinary cortisol (UC) levels or safety. Hormonal, clinical and metabolic parameters were measured at baseline and at 3-month and 6-month follow-up, whereas tumour size was evaluated at baseline and at 6-mont…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismUrinary system030209 endocrinology & metabolismDiseaseSomatostatin analoguesCushing’s disease; Medical treatment; Pasireotide; Pituitary tumour; Somatostatin analoguesBody Mass IndexYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusHumansMedicinePituitary NeoplasmsPituitary ACTH HypersecretionAdverse effectAgedmedicine.diagnostic_testbusiness.industryPituitary tumourCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseaseMagnetic Resonance ImagingPasireotidePasireotideTreatment OutcomeItalychemistry030220 oncology & carcinogenesisCushing’s disease Medical treatment Pasireotide Pituitary tumour Somatostatin analoguesFemaleOriginal ArticleWaist CircumferenceSomatostatinbusinessLipid profileBody mass indexMedical treatment
researchProduct

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence st…

2019

Abstract Purpose Clinical trials have demonstrated the favorable efficacy/safety profile of pasireotide in patients with Cushing’s disease (CD). We report interim long-term results of an ongoing real-world evidence study of subcutaneous pasireotide in patients with CD. Methods Adults with CD receiving pasireotide, initiated before (prior-use) or at study entry (new-use), were monitored for ≤ 3 years during a multicenter observational study (http://clinicaltrials.gov identifier NCT02310269). Primary objective was to assess long-term safety of pasireotide alone or with other CD therapies. Results At the time of this interim analysis, 127 patients had received pasireotide (new-use, n = 31; pri…

AdultMalePediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercortisolism030209 endocrinology & metabolismDiseaseArticleSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInterimmedicineHumansMulticenter Studies as TopicIn patientPituitary ACTH Hypersecretionbusiness.industryPituitary ACTH hypersecretionCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseasePasireotidePasireotideClinical trialTreatment OutcomePituitarychemistryHyperglycemiaFemaleLong term safetySafetySomatostatinbusiness030217 neurology & neurosurgeryPituitary
researchProduct

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy

2022

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analyzed the effect of pasireotide (PAS) on glucose homeostasis. To assess gastro-entero-pancreatic hormones response in diabetic (DM+) and non-diabetic (DM–) patients, 26 patients with CD underwent an MMTT. Ten patients were submitted to a second MMTT after two months of PAS 600 µg twice daily. The DM+ group had significantly higher BMI, waist circumference, glycemia, HbA1c, ACTH le…

Blood GlucoseCushing’s disease; diabetes mellitus; incretin; mixed meal test tolerance test; pasireotidemixed meal test tolerance testGastric Inhibitory PolypeptideIncretinsCatalysisInorganic ChemistryGlucagon-Like Peptide 1HumansInsulinPhysical and Theoretical ChemistryPituitary ACTH HypersecretionMolecular BiologyMealsSpectroscopyGlycated HemoglobinpasireotideC-Peptidediabetes mellituOrganic Chemistrydigestive oral and skin physiologyGeneral MedicineCushing’s diseaseGlucagonincretinComputer Science ApplicationsDiabetes Mellitus Type 2Cushing’s disease; mixed meal test tolerance test; diabetes mellitus; incretin; pasireotidediabetes mellituspasireotide.Insulin ResistanceSomatostatinhormones hormone substitutes and hormone antagonists
researchProduct

Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

2018

Introduction: Cushing’s disease (CD) is characterized by procoagulative profile. Treatment with cortisol-reducing medications might normalize the coagulation impairment potentially eliminating the risk of thromboembolic complications. Aim: The aim of this prospective study is to evaluate the effectiveness of 6–12 months of treatment with pasireotide (Signifor®, Novartis) 600 µg twice daily on coagulative factors in 21 patients (16 females, mean age 46 ± 12.2 years) with CD. Biochemical, hormonal (urinary free cortisol, UFC; late night salivary cortisol, LNSC; ACTH) and coagulative parameters as Protrombin time (PT), aPTT, factors VIII, IX and XI, antithrombin III, protein C, protein S, fibr…

Cortisol secretionAdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterologySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansProspective StudiesProspective cohort studyThromboprophylaxisPituitary ACTH HypersecretionBlood CoagulationClotting factorCoagulationbusiness.industryAnticoagulantCoagulation; Cushing’s disease; Pasireotide; Pituitary; Thromboprophylaxis; Endocrinology Diabetes and Metabolism; EndocrinologyCushing's diseaseCushing’s diseaseMiddle Agedmedicine.diseasePasireotidePasireotideDiabetes and MetabolismCoagulative necrosisTreatment OutcomechemistryPituitary030220 oncology & carcinogenesisConcomitantThromboprophylaxiFemaleBlood Coagulation TestsbusinessSomatostatinEndocrine
researchProduct